ITEM VIEW

Monocytic myeloid-derived suppressor cells in chronic infections

dc.contributor.authorDorhoi, Ancaen_ZA
dc.contributor.authorDu Plessis, Nelitaen_ZA
dc.date.accessioned2019-09-23T12:36:09Z
dc.date.available2019-09-23T12:36:09Z
dc.date.issued2018
dc.identifier.citationDorhoi, A. & Du Plessis, N. 2018. Monocytic myeloid-derived suppressor cells in chronic infections. Frontiers in Immunology, 8:1895, doi:10.3389/fimmu.2017.01895
dc.identifier.issn1664-3224 (online)
dc.identifier.otherdoi:10.3389/fimmu.2017.01895
dc.identifier.urihttp://hdl.handle.net/10019.1/106517
dc.descriptionCITATION: Dorhoi, A. & Du Plessis, N. 2018. Monocytic myeloid-derived suppressor cells in chronic infections. Frontiers in Immunology, 8:1895, doi:10.3389/fimmu.2017.01895.
dc.descriptionThe original publication is available at https://www.frontiersin.org
dc.description.abstractENGLISH ABSTRACT: Heterogeneous populations of myeloid regulatory cells (MRC), including monocytes, macrophages, dendritic cells, and neutrophils, are found in cancer and infectious diseases. The inflammatory environment in solid tumors as well as infectious foci with persistent pathogens promotes the development and recruitment of MRC. These cells help to resolve inflammation and establish host immune homeostasis by restricting T lymphocyte function, inducing regulatory T cells and releasing immune suppressive cytokines and enzyme products. Monocytic MRC, also termed monocytic myeloid-derived suppressor cells (M-MDSC), are bona fide phagocytes, capable of pathogen internalization and persistence, while exerting localized suppressive activity. Here, we summarize molecular pathways controlling M-MDSC genesis and functions in microbial-induced non-resolved inflammation and immunopathology. We focus on the roles of M-MDSC in infections, including opportunistic extracellular bacteria and fungi as well as persistent intracellular pathogens, such as mycobacteria and certain viruses. Better understanding of M-MDSC biology in chronic infections and their role in antimicrobial immunity, will advance development of novel, more effective and broad-range anti-infective therapies.en_ZA
dc.description.urihttps://www.frontiersin.org/articles/10.3389/fimmu.2017.01895/full
dc.format.extent15 pagesen_ZA
dc.language.isoen_ZAen_ZA
dc.publisherFrontiers Media
dc.subjectTuberculosisen_ZA
dc.subjectMyeloid regulatory cellsen_ZA
dc.subjectMonocytesen_ZA
dc.titleMonocytic myeloid-derived suppressor cells in chronic infectionsen_ZA
dc.typeArticleen_ZA
dc.description.versionPublisher's version
dc.rights.holderAuthors retain copyrighten_ZA


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

ITEM VIEW